Braveheart Investment Group plc Update on the Paraytec AD Scanner project
June 14 2021 - 4:40AM
RNS Non-Regulatory
TIDMBRH
Braveheart Investment Group plc
14 June 2021
Reach - a non-regulatory announcement
AIM: BRH
14 June 2021
Braveheart Investment Group plc
("Braveheart" or the "Group")
Update on the P araytec AD Scanner project
Paraytec's grant funded project to deploy its ActiPix(TM)
technology in the field of Alzheimer's disease (AD) diagnosis,
working with a pan-European consortium of Karolinska Institute,
Biomotif, Vrije University Medical Centre Amsterdam (VUMC) and MS
Vision is progressing well. Prototype instruments are being built,
to test blood for protein biomarkers. If successful, these
instruments will be used by clinicians aiming to more accurately
diagnose patients and monitor their treatment.
Pooled plasma samples from AD patients and healthy individuals
have been tested in the laboratory and produced good results. In
the next month, VUMC will begin testing the system with plasma
samples from individual AD patients, to assess the pre-clinical
performance and correlation with clinical diagnosis.
The first fully assembled instrument, incorporating Paraytec's
detector technology, has been produced by MS Vision and shipped to
Karolinska Institute in Sweden for testing. The instrument uses
capillary isoelectric focusing (cIEF), together with ActiPix
technology, to measure the level of protein biomarkers (abnormal
proteoforms) in blood samples. If present, these biomarkers are
indicative of the likely rate of mental decline for a given AD
patient. This is important because such information could be used
by clinicians in early diagnosis to differentiate AD patients from
those with mild cognitive impairment, and also by researchers to
help develop better drugs to counter this devastating disease.
Research conducted by the Alzheimer's Society shows that, in
2019, there were over 850,000 people with dementia in the UK. The
Society considers that more than 520,000 people in the UK have
dementia caused by Alzheimer's disease and this figure is set to
rise.
https://www.alzheimers.org.uk/about-dementia/types-dementia/alzheimers-disease#content-start
The project is due to end in August 2021 and discussions
regarding commercialisation are ongoing with system manufacturers
who are already part of the project team.
During the project Paraytec has developed new cIEF analytical
techniques which dramatically improve signal to noise ratios, far
beyond those of competitor instrumentation. The Paraytec team
believes this breakthrough will lead to new applications for its
ActiPix technology, for example in the biopharmaceutical industry
for quality control in manufacturing therapeutic antibodies.
For further
information:
Braveheart Investment Group plc Tel: 01738 587555
Viv Hallam, Executive Director
Allenby Capital Limited (Nominated Adviser Tel: 020 3328 5656
and Joint Broker)
David Worlidge / George Payne
Peterhouse Capital Limited (Joint Broker) Tel: 020 7469 0936
Heena Karani / Lucy Williams
About Reach announcements
This is a Reach announcement. Reach is an investor communication
service aimed at assisting listed and unlisted (including AIM
quoted) companies to distribute media only / non-regulatory news
releases into the public domain. Information required to be
notified under the AIM Rules for Companies, Market Abuse Regulation
or other regulation would be disseminated as an RNS regulatory
announcement and not on Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUSOWRANUNARR
(END) Dow Jones Newswires
June 14, 2021 04:40 ET (08:40 GMT)
Braveheart Investment (LSE:BRH)
Historical Stock Chart
From Apr 2024 to May 2024
Braveheart Investment (LSE:BRH)
Historical Stock Chart
From May 2023 to May 2024